Medication info

Ezebav Tablet (Ezetimibe)

Prescription medicationTabletExpired
Ingredient · strength
Ezetimibe›10mg / 1 tablet
Manufacturer / importer
Mirae Bio Pharmaceutical Co., Ltd.
Appearance
White to off-white oblong tablet
Packaging
10 tablets/box [10 tablets/PTP X 1], 100 tablets/bottle, 30 tablets/box [10 tablets/PTP X 3]
Approval status
Expired

MFDS item code 202003841 · Approved 2020.05.26

This product's status changed to Expired on 2025.05.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of hypercholesterolemia, mixed dyslipidemia, and homozygous sitosterolemia
Who uses it
Adults
Adult dosage
A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, with or without food. When administered concomitantly with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When administered concomitantly with fenofibrate (in patients with mixed hyperlipidemia), administer with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). Administration in Patients with Hepatic Impairment No dose adjustment is necessary in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Patients Requiring Caution). Administration in Patients with Renal Impairment No dose adjustment is necessary in patients with renal impairment. Administration in Older Adults No dose adjustment is necessary when administering to older adults. Concomitant Administration with Bile Acid Sequestrants This medicine should be administered 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Interactions).

Ingredients

Manufacturer
Mirae Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of hypercholesterolemia, mixed dyslipidemia, and homozygous sitosterolemia

  • Primary hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • homozygous sitosterolemia
View approved original text

This medication is used to reduce cholesterol and various lipid parameters associated with primary hypercholesterolemia and mixed hyperlipidemia. It is especially effective in lowering elevated low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B). Additionally, it is used in conjunction with or as an alternative to other treatments for patients with homozygous familial hypercholesterolemia. For patients with homozygous sitosterolemia, it is administered as an adjunct therapy to reduce plant sterols like sitosterol and campesterol. This medication must be used in conjunction with an appropriate diet, and if there are secondary causes, it is important to treat those first. Thus, this medication is used to reduce the risk of hyperlipidemia and its related atherosclerotic vascular diseases.

Dosage and Administration

Adult dosage

A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, with or without food. When administered concomitantly with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When administered concomitantly with fenofibrate (in patients with mixed hyperlipidemia), administer with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). Administration in Patients with Hepatic Impairment No dose adjustment is necessary in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Patients Requiring Caution). Administration in Patients with Renal Impairment No dose adjustment is necessary in patients with renal impairment. Administration in Older Adults No dose adjustment is necessary when administering to older adults. Concomitant Administration with Bile Acid Sequestrants This medicine should be administered 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Interactions).

Precautions

This medication should not be used in patients who have hypersensitivity to any components of this medication. It is advisable not to use this medication in conjunction with certain lipid-lowering agents (statins) in patients with severely impaired liver function or those with persistently elevated serum aminotransferase levels without explanation. Pregnant or breastfeeding women should not take this medication in combination with statins or fenofibrate. This medication is not recommended for patients with moderate to severe liver impairment and should be used cautiously. During treatment with this medication, symptoms such as headache, fatigue, abdominal pain, diarrhea, and myalgia may occur, and if these symptoms persist or worsen, consultation with a physician is necessary. If myalgia, muscle weakness, or unexplained myasthenia occurs, inform the medical staff immediately, and discontinue the medication if necessary. Regular liver function tests may be required, so liver enzyme levels should be monitored regularly, and report any symptoms of liver dysfunction to a physician promptly. Interactions may occur when taken with certain medications, so it is essential to inform your healthcare provider of any medications you are currently taking. Women who are pregnant or planning to become pregnant must consult with a physician before taking this medication, as do those who are breastfeeding. The use of this medication is not recommended for children under 6 years of age, and in children and adolescents over 6 years old, it should be used under a physician's supervision. Elderly patients may use this medication; however, caution is advised as sensitivity may vary by age. In cases of overdose, there are no specific antidotes, so treatment will depend on symptoms, and the prescribed dosage should be strictly followed. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Fatigue, abdominal pain, diarrhea, viral infection, pharyngitis, sinusitis, arthralgia, low back pain, cough, chest pain, dizziness, headache, constipation, bloating, nausea, increased AST, increased ALT, myalgia, myopathy, rhabdomyolysis, elevated amino transferase levels, gallbladder-related adverse reactions, cholelithiasis, cholecystitis, anaphylaxis, urticaria, rash, angioedema, increased creatine phosphokinase levels, hepatitis, thrombocytopenia, pancreatitis, sensory disturbances, depression, Stevens-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, drug reactions accompanied by systemic symptoms, erythema multiforme, drug-induced liver injury, chest tightness, chest discomfort, edema, weakness, generalized edema, diabetic neuropathy, tremors, upper abdominal pain, vomiting, gastritis, dry mouth, epigastric discomfort, belching, gastrointestinal disturbances, gastroesophageal reflux disease, tongue disorders, palpitations, congestive heart failure, myocardial ischemia, flushing, sputum, nasal discharge, limb pain, diabetes, hypoglycemia, anemia, splenomegaly, conjunctival injection, renal failure, liver dysfunction, increased serum creatinine, increased blood pressure, increased blood urea, increased serum creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, and it should be stored in a tightly sealed container. Additionally, avoid extremely hot or cold places, and it is advisable to store it at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White to off-white oblong tablet

Package unit

10 tablets/box [10 tablets/PTP X 1], 100 tablets/bottle, 30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.